Furthermore, given the galectin‐9 (Gal‐9)/T cell immunoglobulin and mucin‐domain containing‐3 (TIM‐3) pathway is gaining significant attention in cancer immunotherapy as an additional inhibitory checkpoint system, its expression in IDH‐mutant glioma was also examined by Sørensen et al. This evidence concerns the gene IDH2 and cancer.